• Journal of Yeungnam Medical Science
• /
• 제34권1호
• /
• pp.115-118
• /
• 2017

Insulin autoimmune syndrome (IAS) is characterized by spontaneous hypoglycemia, extremely high serum insulin levels, and high titers of autoantibodies against endogenous insulin, in the absence of exogenous insulin injection. IAS often occurs following exposure to sulfhydryl-containing drugs, including alpha-lipoic acid (ALA). A 30-year-old woman without diabetes visited our outpatient clinic with recurrent hypoglycemia. She had been taken ALA for weight reduction since 3 weeks ago. Further hypoglycemia work up revealed very high insulin levels, C-Peptide levels and positive insulin antibodies. And conventional imaging examinations were negative for insulinoma or other pancreatic tumors. Finally, the diagnosis of Insulin autoimmune syndrome (IAS) was made. Following the cessation of ALA, hypoglycemia improved, with no medication, and the patient experienced no further hypoglycemic attacks over the next month. The use of ALA as a nutritional supplement is increasing. We report a case of IAS associated with ALA in a non-diabetic patient.

• Diabetes and Metabolism Journal
• /
• 제42권6호
• /
• pp.451-464
• /
• 2018

Latent autoimmune diabetes in adults (LADA) is a heterogeneous disease characterized by a less intensive autoimmune process and a broad clinical phenotype compared to classical type 1 diabetes mellitus (T1DM), sharing features with both type 2 diabetes mellitus (T2DM) and T1DM. Since patients affected by LADA are initially insulin independent and recognizable only by testing for islet-cell autoantibodies, it could be difficult to identify LADA in clinical setting and a high misdiagnosis rate still remains among patients with T2DM. Ideally, islet-cell autoantibodies screening should be performed in subjects with newly diagnosed T2DM, ensuring a closer monitoring of those resulted positive and avoiding treatment of hyperglycaemia which might increase the rate of ${\beta}-cells$ loss. Thus, since the autoimmune process in LADA seems to be slower than in classical T1DM, there is a wider window for new therapeutic interventions that may slow down ${\beta}-cell$ failure. This review summarizes the current understanding of LADA, by evaluating data from most recent studies, the actual gaps in diagnosis and management. Finally, we critically highlight and discuss novel findings and future perspectives on the therapeutic approach in LADA.

• 동아시아식생활학회지
• /
• 제17권2호
• /
• pp.205-212
• /
• 2007

This study was designed to investigate a natural medicinal multi-plants extract (BG515), which consisted of multi extracts of Mori folium, Rehmannia glutinosa Liboschitz, Dioscorea japonica, Lycii fructus, and Astragalus radix, on blood glucose, insulin levels, and serum malondialdehyde (MDA) concentrations in streptozotocin-induced diabetic rats. Streptozotocin (STZ) induces a type 1 diabetes mellitus in rats. Type 1 is usually characterized by the presence of islet cell autoantibodies (ICA), autoantibodies to insulin (IAA), and autoantiboides to glutamic acid decarboxylase (GAD), which identify the autoimmune process that leads to $\beta-cell$ destruction. Thirty-five male Sprague-Dawley (SD) rats weighing $150\sim170g$ each (6 weeks old) were randomly divided into one control (Group A) and 4 STZ-induced diabetic groups, and were subjected to one of the following treatment for 12 weeks. Groups A and B were fed basal diets and Group C, D, and E received the same diets as groups A and B, but with supplements of 150 mg/kg, 300 mg/kg, and 600 mg/kg of BG515 orally for 12 weeks, respectively. Diabetes was induced in Groups B, C, D, and E by intravenous injection of 45 mg/kg of STZ per body weight in sodium citrate buffer (pH 4.5) via the tail vein. In the BG515 groups, we found increases in serum insulin levels, compared to the STZ-control group, but these data were not significant. In contrast, blood glucose and serum MDA concentrations decreased in the BG515 groups compare to the STZ-control group. At the 5th week, in all the BG515 administered groups, there were decreases in serum blood glucose levels compared to the STZ- control group, and this activity was very strong in the BG515-1 group at the 12th week. These results suggest that natural bio-complex compounds (BG515) may slightly suppress STZ-induced changes in serum MDA concentration via the maintenance of serum insulin levels, due to the prevention of $\beta-cell$ and glucagon destruction by STZ.

• Clinical and Experimental Pediatrics
• /
• 제53권3호
• /
• pp.414-419
• /
• 2010

목 적 : 제 1형 당뇨병에서 보이는 자가 항체와 질환의 진행에 따른 변화와의 관계는 여러 연구에서 보고되었고, 항체가가 높을수록 진행의 정도가 급격하였다. 따라서 진단 당시에 시행한 자가 항체의 발현 여부에 따라 임상 발현 정도가 다를 것으로 생각하여, 자가 항체 유무에 따라 임상 양상과 검사 소견의 차이가 있는지를 확인하고자 하였다. 방 법 : 1999년 4월부터 2008년 3월까지 3개 대학병원에 내원하여 제 1형 당뇨병으로 진단받은 18세 미만 환자 중 처음 진단 당시에 췌장 자가 항체인 GADA 혹은 IAA의 검사를 시행하였던 96명에서 진단 당시 시행한 혈액 검사 및 임상 양상을 항체 그룹에 따라 나누어 비교 분석하였다. 결 과 : GADA는 87명의 환자에서 검사가 이루어 졌고, 이 중 48명(55.2%)에서 양성을 보였다. IAA는 88명 중 35명(39.8%)이 양성을 보였다. 두가지 항체를 모두 검사한 환자는 83명이었고, 이 중 22.8%에서 두 항체가 모두 검출되었고, 38.6%에서는 모두 음성을 보였다. 1가지 이상의 항체를 갖는 환자군에서는 음성군에 비해 비교적 어린 나이에 당뇨병이 발생하였고, 낮은 BMI, 낮은 혈청 교정 Na 수치 및 낮은 혈청 오스몰농도를 보였다(P <0.05). 자가 항체 중 GADA 양성군과 음성군 사이의 검사소견 상에서도 같은 차이를 보였다. 그러나 IAA 항체 유무에 따른 비교에서는 발생 연령이외는 두 군사이에 임상 및 검사소견상 유의한 차이를 볼 수 없었다. 결 론 : 항체 양성군과 음성군 사이에서 보이는 대사적 결과의 차이는 비교적 적었으나 GADA와 IAA 항체의 양성율은 어린 연령에서 높았다. 따라서 비교적 어린 연령에 발생하는 1형 당뇨병에서는 질환을 처음으로 진단할 때자가 항체 유무를 확인하고, 만약 항체가 확인되면 향후 집중적인 인슐린 치료를 시행하여 보다 좋은 예후를 유도하는데 도움이 될 수 있을 것이다.